Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBT Margin (2020 - 2025)

Historic EBT Margin for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 9210.61%.

  • Ovid Therapeutics' EBT Margin fell 11146500.0% to 9210.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 556.01%, marking a year-over-year decrease of 5414600.0%. This contributed to the annual value of 4670.14% for FY2024, which is 86816400.0% up from last year.
  • As of Q3 2025, Ovid Therapeutics' EBT Margin stood at 9210.61%, which was down 11146500.0% from 74.68% recorded in Q2 2025.
  • Ovid Therapeutics' 5-year EBT Margin high stood at 5042.01% for Q2 2024, and its period low was 107798.33% during Q3 2022.
  • Over the past 5 years, Ovid Therapeutics' median EBT Margin value was 7873.08% (recorded in 2025), while the average stood at 12315.98%.
  • Within the past 5 years, the most significant YoY rise in Ovid Therapeutics' EBT Margin was 974744800bps (2023), while the steepest drop was -184521400bps (2023).
  • Over the past 5 years, Ovid Therapeutics' EBT Margin (Quarter) stood at 11.92% in 2021, then surged by 57bps to 5.17% in 2022, then plummeted by -33bps to 6.88% in 2023, then tumbled by -117625bps to 8095.95% in 2024, then dropped by -14bps to 9210.61% in 2025.
  • Its EBT Margin was 9210.61% in Q3 2025, compared to 74.68% in Q2 2025 and 7873.08% in Q1 2025.